COMPANY OVERVIEW

None

---

LOCATION

---

THERAPEUTIC AREAS

---

WEBSITE

None

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

PRESS RELEASES

Mar 17, 2023

Lutris Pharma Presents Data From a Real-World Analysis of Skin Toxicity From EGFR Inhibitors - an Unmet Challenge, at the 2023 American Academy of Dermatology Annual Meeting USA - English Israel - English

Feb 16, 2023

Lutris Pharma to Present at the 16th Annual European Life Sciences CEO Forum in March

Oct 24, 2022

Lutris Pharma's Founder and Chairman of the Board Receives $5.0 Million Grant from the California Institute of Regenerative Medicine (CIRM) to Develop LUT017 for Wound Healing USA - English USA - English

Oct 24, 2022

Lutris Pharma's Founder and Chairman of the Board Receives $5.0 Million Grant from the California Institute of Regenerative Medicine (CIRM) to Develop LUT017 for Wound Healing USA - English USA - English

Sep 14, 2022

Lutris Pharma Receives Notice of Allowance for Patent Covering the Use of B-Raf Inhibitors in MEK Inhibitor induced rash USA - English Israel - English

For More Press Releases

---